CN118660873A - 二肽基肽酶抑制剂化合物的盐及晶型 - Google Patents

二肽基肽酶抑制剂化合物的盐及晶型 Download PDF

Info

Publication number
CN118660873A
CN118660873A CN202380015239.3A CN202380015239A CN118660873A CN 118660873 A CN118660873 A CN 118660873A CN 202380015239 A CN202380015239 A CN 202380015239A CN 118660873 A CN118660873 A CN 118660873A
Authority
CN
China
Prior art keywords
compound
formula
salt
ray powder
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380015239.3A
Other languages
English (en)
Chinese (zh)
Inventor
范江
窦赢
宫正
朱凤飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haisco Pharmaceutical Group Co Ltd
Original Assignee
Tibet Haisike Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibet Haisike Pharmaceutical Co ltd filed Critical Tibet Haisike Pharmaceutical Co ltd
Publication of CN118660873A publication Critical patent/CN118660873A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cooling Or The Like Of Semiconductors Or Solid State Devices (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380015239.3A 2022-02-22 2023-02-21 二肽基肽酶抑制剂化合物的盐及晶型 Pending CN118660873A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022101608625 2022-02-22
CN202210160862 2022-02-22
PCT/CN2023/077409 WO2023160542A1 (zh) 2022-02-22 2023-02-21 二肽基肽酶抑制剂化合物的盐及晶型

Publications (1)

Publication Number Publication Date
CN118660873A true CN118660873A (zh) 2024-09-17

Family

ID=87764787

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380015239.3A Pending CN118660873A (zh) 2022-02-22 2023-02-21 二肽基肽酶抑制剂化合物的盐及晶型

Country Status (13)

Country Link
US (1) US20250188067A1 (https=)
EP (1) EP4484414A4 (https=)
JP (1) JP2025508792A (https=)
KR (1) KR20240153351A (https=)
CN (1) CN118660873A (https=)
AU (1) AU2023225835A1 (https=)
CA (1) CA3243683A1 (https=)
CL (1) CL2024002490A1 (https=)
IL (1) IL314852A (https=)
MX (1) MX2024010180A (https=)
TW (1) TW202342466A (https=)
WO (1) WO2023160542A1 (https=)
ZA (1) ZA202407225B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314855A (en) * 2022-02-22 2024-10-01 Haisco Pharmaceuticals Pte Ltd Preparation method of nitrogen-containing heterocyclic compound
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
NO2699580T3 (https=) * 2014-01-24 2018-02-24
CN115996923B (zh) * 2020-08-26 2025-07-18 海思科医药集团股份有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN114106005B (zh) * 2020-08-26 2025-08-01 西藏海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
US20240150335A1 (en) * 2021-02-05 2024-05-09 Medshine Discovery Inc. Fused ring derivatives containing 1,4-oxazepane

Also Published As

Publication number Publication date
EP4484414A4 (en) 2026-01-28
WO2023160542A1 (zh) 2023-08-31
AU2023225835A1 (en) 2024-10-03
ZA202407225B (en) 2025-12-17
EP4484414A1 (en) 2025-01-01
CL2024002490A1 (es) 2024-12-13
MX2024010180A (es) 2024-08-27
JP2025508792A (ja) 2025-04-10
TW202342466A (zh) 2023-11-01
IL314852A (en) 2024-10-01
US20250188067A1 (en) 2025-06-12
KR20240153351A (ko) 2024-10-22
CA3243683A1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
US8884013B2 (en) Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof
CN118696040A (zh) 一种二肽基肽酶1抑制剂多晶型物及其制备方法和用途
EP3805229B1 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
CN118660873A (zh) 二肽基肽酶抑制剂化合物的盐及晶型
CN112142679A (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
CN115433246A (zh) 葡萄糖胺衍生物的晶型、制备方法及用途
US10513513B2 (en) Salts of quinazoline derivative or crystals thereof, and the process for producing thereof
TW202334077A (zh) 一種三伸乙基四胺四氫氯化物及其製備方法與組合物
CN106279127B (zh) 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
KR101557832B1 (ko) (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
JP2022508864A (ja) チロシンキナーゼ阻害剤のマレイン酸塩の結晶形及びその調製方法
EA053095B1 (ru) Соль и кристаллическая форма соединения, являющегося ингибитором дипептидилпептидазы
EP3517529B1 (en) Salt of quinazoline derivative, preparation method therefor and application thereof
HK40121338A (zh) 一种嘧啶苯胺类化合物的晶型、制备方法及应用
WO2024169896A1 (zh) 一种苯并氮杂芳环衍生物的盐、晶型及其在医药上的应用
HK40082657B (zh) 一种药物组合物、制剂及其制备方法和应用
TW202440585A (zh) MDM2-p53抑制劑之晶型及醫藥組合物
EA051477B1 (ru) Полиморф ингибитора дипептидилпептидазы 1, способ его получения и применение
HK40040064B (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
CN116239568A (zh) 5-ht1f受体激动剂的新晶型及其制备方法
HK40040064A (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40111064

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20250221

Address after: No.17 Sanxiang Avenue, Zedang Town, Shannan City, Tibet Autonomous Region

Applicant after: HAISCO PHARMACEUTICAL Group Inc.

Country or region after: China

Address before: 856099 Xingfu Jiayuan Economic Development Zone, Gyerba, Nedong District, Shannan City, Tibet Autonomous Region

Applicant before: Tibet Haisike Pharmaceutical Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right